Biomarkers for monitoring patients with cardiac amyloidosis during transthyretin-stabilizer therapy

31 August 2024 (10:00 - 10:50)

Organised by:

Abstract

Sign in to view the resources

Slides

About the speaker

Doctor Julia Kirsten Vogel

University of Duisburg-Essen - West-German Heart and Vascular Centre, Essen (Germany)

8 More presentations in this session

Presentation thumbnail

Delays in diagnosis and treatment initiation of ATTR cardiac amyloidosis: a real-world data analysis

Doctor J. Vogel (Essen, DE)

Abstract Slides Video

Presentation thumbnail

Transthyretin stabiliser therapy in patients with transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis

Mr V. Ribeiro (Teresina, BR)

Abstract Slides Video

Presentation thumbnail

Prevalence of transthyretin amyloid cardiomyopathy in patients hospitalised for heart failure with preserved ejection fraction in an LATAM center.

Mr S. Decotto (Buenos Aires, AR)

Abstract Slides Video

Presentation thumbnail

Relationship between changes in renal function after acute phase of tafamidis administration and left ventricular diastolic function at mid-term follow-up in transthyretin cardiac amyloidosis

Ms A. Senda (Kobe, JP)

Abstract Slides

Presentation thumbnail

Prevalence of amyloidosis among patients with mild to severe aortic stenosis. Validation of screening parameters.

Doctor F. Voss (Duesseldorf, DE)

Abstract Slides

Access the full session

Session thumbnail

Cardiac amyloidosis, sarcoidosis, and inflammation

The Event

Event poster

ESC Congress 2024

31 August 2024 10:00 CET

You may be interested in

Congress Session

Clinical phenotypes of heart failure with preserved ejection fraction

Webinar

Advanced heart failure therapy in HF patients with preserved and mildly reduced ejection fraction

Webinar

Acute heart failure in patients with preserved ejection fraction (AHFPEF)

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources